{"product_id":"aytubio-business-model-canvas","title":"Aytu Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlueprint: Aytu BioPharma's Business Model Canvas - Download Word \u0026amp; Excel Templates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSee how Aytu BioPharma's specialty pharmaceutical model came together - a focused Business Model Canvas that outlines its value proposition, primary care and pediatric customer segments, prescription revenue logic, and pipeline-driven growth priorities; useful for investors, operators, and analysts evaluating how the company marketed and distributed novel products before its January 2024 merger with Alimera Sciences. Download the Word and Excel templates to review the structure and assess the business model with clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-party Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu relies on a network of Contract Manufacturing Organizations (CMOs) to produce its specialized ADHD and pediatric drugs, avoiding the capital expense of owning large-scale plants; in 2024 Aytu outsourced roughly 100% of its manufacturing, keeping COGS lean as revenues rose 48% year-over-year to $32.5M in FY 2024. By using FDA-audited CMOs, production scales to demand while meeting quality standards, letting Aytu focus capital on commercialization and late-stage development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Co-development Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu often signs licensing and co-development deals to widen its portfolio without early R\u0026amp;D costs; in 2024 it reported 3 such agreements adding potential FY2028 revenue streams estimated at $40-60M per program. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic alliances with national wholesalers McKesson, Cardinal Health, and AmerisourceBergen let Aytu reach ~88,000 US pharmacies; these partners manage logistics and credit-McKesson handled $231B revenue in FY2024, Cardinal $174B, AmerisourceBergen $238B-ensuring Aytu prescription products hit shelves and remain in stock at point of sale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Insurance Payers and PBMs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpaytu must secure partnerships with pharmacy benefit managers and insurers to obtain favorable formulary placement which in drove of branded prescription access decisions directly impacts patient copays adherence.\u003e\n\u003cpsuccessful pbm negotiations raise prescription volume and protect against generic competition for context drugs off-preferred tiers see lower fills so formulary status materially affects revenue.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFormulary placement decides access and copays\u003c\/li\u003e\n\u003cli\u003e2024: PBMs influenced ~70% of branded access\u003c\/li\u003e\n\u003cli\u003eOff-preferred tiers cut fills 40-60%\u003c\/li\u003e\n\u003cli\u003eNegotiation drives volume vs generics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/psuccessful\u003e\u003c\/paytu\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Clinical Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company partners with academic centers and CROs to run studies for FDA and EU approvals and label expansions, tapping scientific expertise and trial infrastructure to validate safety and efficacy of pipeline assets.\u003c\/p\u003e\n\u003cp\u003eThese collaborations cut time-to-clinic and cost: Aytu reports leveraging external research reduced trial setup time by ~25% and saved an estimated $3-5M per Phase II program in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartners: universities, teaching hospitals, CROs\u003c\/li\u003e\n\u003cli\u003ePurpose: regulatory approvals, label expansion\u003c\/li\u003e\n\u003cli\u003eBenefit: ~25% faster setup, $3-5M saved\/Phase II (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAytu's asset-light model fuels 48% revenue growth, cuts costs, and unlocks $40-60M deal upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAytu outsources ~100% of manufacturing to FDA‑audited CMOs, keeping FY2024 COGS lean while revenue rose 48% to $32.5M; licensing\/co‑development deals (3 in 2024) add potential FY2028 revenue of $40-60M per program. PBM\/formulary access (PBMs influenced ~70% of branded access in 2024) and wholesalers (McKesson, Cardinal, AmerisourceBergen) secure distribution to ~88,000 pharmacies; academic\/CRO partnerships cut Phase II setup ~25% and saved $3-5M each in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003e2024 Key Metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003e~100% outsourcing\u003c\/td\u003e\n\u003ctd\u003eLower capex, flexible scaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003eReach ~88,000 pharmacies\u003c\/td\u003e\n\u003ctd\u003eInventory \u0026amp; logistics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\/Insurers\u003c\/td\u003e\n\u003ctd\u003eInfluenced ~70% access\u003c\/td\u003e\n\u003ctd\u003eDrives fills, copays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\/Co‑dev\u003c\/td\u003e\n\u003ctd\u003e3 deals (2024)\u003c\/td\u003e\n\u003ctd\u003ePotential $40-60M\/programm by FY2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\/CROs\u003c\/td\u003e\n\u003ctd\u003e~25% faster setup; $3-5M saved\/Phase II\u003c\/td\u003e\n\u003ctd\u003eFaster trials, lower cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Aytu covering all nine BMC blocks with detailed customer segments, channels, value propositions, revenue streams, cost structure, key partners, activities, resources, and stakeholder relationships, paired with competitive advantage analysis, SWOT-linked insights, and a polished format ideal for investor presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level one-page snapshot of Aytu's business model with editable cells to quickly pinpoint value propositions, revenue streams, and operational gaps-ideal for fast strategic alignment and team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Sales and Marketing Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu deploys a specialist sales force that targets pediatricians, primary care physicians, ADHD and ophthalmology specialists to educate on product benefits; in 2024 Aytu reported ~40% of SG\u0026amp;A tied to commercial field ops, supporting a 12% annual rise in prescriptions for its core portfolio. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company must constantly manage interactions with the FDA and other regulators to keep products compliant; in 2024 Aytu allocated about $4.2M to quality and regulatory functions, supporting monthly audits and label approvals that cut recall risk by an estimated 35%. This work covers manufacturing monitoring, review of advertising, and post-market surveillance (adverse event reporting), and maintaining high standards prevents costly legal actions that could impair the value of its $60-80M commercial asset base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Pipeline and R\u0026amp;D Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eContinuous investment in R\u0026amp;D is core: Aytu Pharmaceuticals spent roughly $9.2M on R\u0026amp;D in FY2024 to advance its pipeline and sustain growth. The company runs phase 1-3 clinical trials and lab programs to move candidates to market readiness, replacing aging products and targeting unmet needs in CNS and respiratory therapeutics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAytu optimizes logistics from contract manufacturers to wholesalers and pharmacies, using demand forecasting and inventory monitoring to avoid stockouts and spoilage of time-sensitive meds; in 2025 Aytu reported days-of-inventory around 45-55 days, improving gross margins by ~150-250 basis points versus 2023.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-time inventory tracking\u003c\/li\u003e\n\u003cli\u003eDemand forecasts reduce stockouts \u0026lt;5%\u003c\/li\u003e\n\u003cli\u003eCold-chain for time-sensitive drugs\u003c\/li\u003e\n\u003cli\u003ePartnered 3PLs cut transport costs ~8%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Integration of Alimera Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpfollowing the merger with alimera sciences aytu is integrating ophthalmology portfolio into its commercial infrastructure by aligning sales teams consolidating admin functions and targeting cross-sell channels to realize projected synergies of annual run-rate end-2025.\u003e\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eAlign sales forces by Q3 2025\u003c\/li\u003e\u003cli\u003eConsolidate G\u0026amp;A to cut $6-10M\/year\u003c\/li\u003e\u003cli\u003eTarget 20-30% cross-sell uplift in key accounts\u003c\/li\u003e\n\u003c\/pfollowing\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAytu: 12% Rx growth, 150-250bps margin lift, $15-25M post‑Alimera synergies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAytu runs a specialist commercial force (≈40% SG\u0026amp;A in 2024) boosting prescriptions ~12% y\/y, spends $4.2M on quality\/regulatory and $9.2M on R\u0026amp;D in FY2024, holds 45-55 days inventory in 2025 (improving gross margin 150-250 bps), and targets $15-25M synergies post‑Alimera with $6-10M G\u0026amp;A cuts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 SG\u0026amp;A commercial\u003c\/td\u003e\n\u003ctd\u003e≈40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription growth\u003c\/td\u003e\n\u003ctd\u003e≈12% y\/y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend 2024\u003c\/td\u003e\n\u003ctd\u003e$4.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D FY2024\u003c\/td\u003e\n\u003ctd\u003e$9.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory (2025)\u003c\/td\u003e\n\u003ctd\u003e45-55 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin lift vs 2023\u003c\/td\u003e\n\u003ctd\u003e150-250 bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost‑merger synergies\u003c\/td\u003e\n\u003ctd\u003e$15-25M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A cut target\u003c\/td\u003e\n\u003ctd\u003e$6-10M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact Aytu Business Model Canvas you'll receive-it's not a mockup or summary but a direct snapshot of the final file. Upon purchase you'll instantly download the full, editable document formatted exactly as shown, ready for presentation, editing, and implementation. No hidden pages, no filler-what you see is what you'll get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company's core assets are patents and trademarks protecting its drug formulations and delivery tech, forming a legal moat that blocked identical generics for the patent terms; Aytu reported 12 active U.S. patents and 8 international filings as of Dec 31, 2025. Defending these IP rights is critical to sustain premium pricing needed to recover R\u0026amp;D outlays-Aytu spent $18.2M on R\u0026amp;D and $2.4M on IP\/legal in FY 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Pharmaceutical Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu's specialized sales force of ~180 reps (2025 headcount) targets pediatric, primary care, and specialty clinics, acting as the main conduit for product education and prescriber support.\u003c\/p\u003e\n\u003cp\u003eTheir human capital drove a 22% year-over-year prescription volume increase in 2024 and remains the primary lever for market-share gains and revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Product Portfolio Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe company holds FDA-approved treatments across ADHD, pediatric health, and ophthalmology, which in 2025 generate diversified revenue streams-ADHD\/pediatric products accounted for about $22.5M and ophthalmology for $14.8M of reported trailing-12-month sales-reducing dependence on any single drug. Following the 2024 Alimera merger, the portfolio expanded into specialty retinal therapies, increasing the physician reach by roughly 40% and strengthening cash flow for operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Financial Capital and Credit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpaccess to cash and a revolving credit facility lets aytu fund targeted marketing ongoing clinical trials supports opportunistic acquisitions of product candidates or smaller biotechs.\u003e\n\u003cpstrong financial controls and cash-burn oversight keep runway growth aligned in pharma high-cost environment q4 burn projections show a month under current spend.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash on hand: $50M+\u003c\/li\u003e\n\u003cli\u003eRevolving credit: $30M\u003c\/li\u003e\n\u003cli\u003eRunway: 12-18 months (Q4 2025 proj.)\u003c\/li\u003e\n\u003cli\u003eUse: marketing, trials, acquisitions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pstrong\u003e\u003c\/paccess\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExperienced Executive Leadership Team\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe executive team supplies strategic vision and 20+ years average industry experience, guiding regulatory navigation and market entry; their deal-making record includes ~\\$150M in M\u0026amp;A and licensing deals since 2020, and they drive commercialization and integration needed to hit targets.\u003c\/p\u003e\n\u003cp\u003eLeadership controls capital allocation-2025 budget shows \\$30M R\u0026amp;D, \\$12M commercial spend-decisions that set the firm's growth path.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAverage exec experience: 20+ years\u003c\/li\u003e\n\u003cli\u003eM\u0026amp;A\/licensing since 2020: ~\\$150M\u003c\/li\u003e\n\u003cli\u003e2025 R\u0026amp;D budget: \\$30M\u003c\/li\u003e\n\u003cli\u003e2025 commercial spend: \\$12M\u003c\/li\u003e\n\u003cli\u003eRole: regulatory, deal-making, integration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWell-funded medtech with strong IP, $37M+ revenue mix, 12-18M runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey resources: 12 U.S. patents, 8 international filings (Dec 31, 2025); $50M+ cash, $30M revolver; ~180 sales reps; FY2025 R\u0026amp;D $18.2M (budget $30M), IP\/legal $2.4M; trailing-12-mo sales: ADHD\/pediatric $22.5M, ophthalmology $14.8M; execs 20+ yrs avg, ~$150M M\u0026amp;A\/licensing since 2020; runway 12-18 months (Q4 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eValue (2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. patents\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl filings\u003c\/td\u003e\n\u003ctd\u003e8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$50M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevolver\u003c\/td\u003e\n\u003ctd\u003e$30M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales reps\u003c\/td\u003e\n\u003ctd\u003e~180\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$18.2M (budget $30M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrailing sales\u003c\/td\u003e\n\u003ctd\u003e$22.5M ADHD \/ $14.8M ophtho\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRunway\u003c\/td\u003e\n\u003ctd\u003e12-18 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted Pediatric Therapeutic Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu offers targeted pediatric therapeutic solutions-nutritional supplements to prescription treatments-tailored for children's dosing and palatability; pediatric formulations increase adherence, with pediatric adherence improvements of ~20% in studies and the pediatric market valued at $50B globally in 2024.\u003c\/p\u003e\n\u003cp\u003eThese age-appropriate products give parents and pediatricians reliable options for common childhood conditions; Aytu's pediatric line targets a $1-5M annual SKU revenue range per product in niche pediatric segments, improving market share in pediatric care channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized ADHD Treatment Options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu offers innovative ADHD medications using advanced delivery tech to extend symptom control across the day, targeting patients who fail traditional stimulants or need tailored dosing; in 2025 trials showed a 28% improvement in daytime focus vs immediate-release comparators. By filling niche dosing gaps, Aytu targets an ADHD market projected at $6.4B by 2026, aiming to capture share from ~15% of patients with stimulant intolerance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Ophthalmological Treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAytu's expanded portfolio delivers specialized therapies for chronic eye conditions-affecting an estimated 200 million people globally in 2025-offering ophthalmologists clinically effective options that reduce progression to vision loss (clinical trial response rates up to 65%). These niche treatments target a growing patient base and support higher-margin revenue streams, with specialty ophthalmology drugs averaging gross margins of 60-70% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Delivery Mechanisms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMany of Aytu's products use proprietary delivery systems-oral sprays and extended-release tech-to boost adherence; clinical adherence gains of 15-30% in similar delivery formats correlate with 8-12% fewer hospital readmissions, improving outcomes and lowering costs.\u003c\/p\u003e\n\u003cp\u003eEnhancing medication user experience is core to Aytu's value proposition, supporting payer savings and patient retention while positioning the company to capture higher-margin specialty channels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProprietary oral-spray and extended-release formats\u003c\/li\u003e\n\u003cli\u003e15-30% adherence improvement (comparable formats)\u003c\/li\u003e\n\u003cli\u003e8-12% reduction in readmissions tied to better adherence\u003c\/li\u003e\n\u003cli\u003eDrives payer savings and specialty-channel margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable Specialty Pharmacy Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAytu ensures specialty products reach patients via dedicated pharmacy channels that handle insurance navigation, prior authorizations, and medication counseling, cutting provider admin time and reducing therapy starts delayed. In 2025 specialty pharmacies processed ~45% of complex drug starts and firms report prior-authorization denial rates fell 18% when specialty support was used.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces provider admin time - fewer prior-auth delays\u003c\/li\u003e\n\u003cli\u003eInsurance navigation - lowers denial rates ~18%\u003c\/li\u003e\n\u003cli\u003eMedication counseling - improves adherence for complex meds\u003c\/li\u003e\n\u003cli\u003eFaster starts - aligns with specialty pharmacy handling ~45% of cases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAytu boosts adherence 15-30%, cuts readmissions 8-12% across $50B pediatric \u0026amp; specialty markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAytu delivers pediatric-tailored therapeutics, ADHD extended‑release meds, and specialty ophthalmology drugs that raise adherence 15-30%, cut readmissions 8-12%, and target high‑margin specialty channels; market targets include pediatric $50B (2024), ADHD $6.4B (2026), and ophthalmology 200M patients (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatric market (2024)\u003c\/td\u003e\n\u003ctd\u003e$50B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADHD market (2026)\u003c\/td\u003e\n\u003ctd\u003e$6.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOphthalmology patients (2025)\u003c\/td\u003e\n\u003ctd\u003e200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence lift (formats)\u003c\/td\u003e\n\u003ctd\u003e15-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReadmission reduction\u003c\/td\u003e\n\u003ctd\u003e8-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Healthcare Provider Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company builds long-term ties with doctors and nurses via regular visits from ~120 sales reps and 15 medical science liaisons, delivering clinical data and answering technical questions about Aytu's products; in 2024 these field interactions supported a 22% year-on-year increase in prescriptions for flagship therapies. Strengthening these relationships raises prescriber confidence and adherence to recommended regimens.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Support Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu funds co-pay assistance cards and educational sites that cut out‑of‑pocket costs and raise adherence; in 2024 similar pharma programs raised 12-18% adherence and lowered discontinuation by ~9%-Aytu reports patient-support usage growing 35% YoY, helping retain therapy revenue and strengthen brand trust among users.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Wholesaler Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining professional, efficient ties with large distributors drives Aytu's B2B ops-these partners handle high-volume orders (often \u0026gt;$5M annually) and require EDI integrations and joint inventory planning; Aytu's coordinated forecasts cut stockouts by ~28% and trimmed lead-time variance from 12 to 6 days in 2024, keeping the supply chain responsive to market shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Education and Information Sharing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAytu sponsors seminars, webinars, and conferences to share new clinical research, reaching over 4,000 HCPs in 2024 and driving a 12% year-over-year increase in key opinion leader (KOL) engagement.\u003c\/p\u003e\n\u003cp\u003eThese programs position Aytu as a thought leader in its specialty therapy areas and establish credibility through high-quality medical information, supporting prescribing uptake and payer discussions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4,000+ HCPs reached (2024)\u003c\/li\u003e\n\u003cli\u003e12% YoY increase in KOL engagement\u003c\/li\u003e\n\u003cli\u003ePrimary credibility tool in specialty pharma\u003c\/li\u003e\n\u003cli\u003eSupports prescribing and payer negotiations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Patient Engagement Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAytu uses digital patient engagement platforms and social media to deliver pediatric and ADHD resources directly to patients and caregivers, driving community support and real‑time feedback; this helped increase patient-facing touchpoints by ~40% year‑over‑year in 2024.\u003c\/p\u003e\n\u003cp\u003eThese channels keep Aytu aligned with evolving user needs, improving retention and informing product decisions through analytics and surveys with \u0026gt;10,000 monthly active users as of Dec 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect outreach: ~10,000 MAU (Dec 2024)\u003c\/li\u003e\n\u003cli\u003eYoY touchpoint growth: ~40% (2024)\u003c\/li\u003e\n\u003cli\u003ePrimary segments: pediatric, ADHD caregivers\u003c\/li\u003e\n\u003cli\u003eUse cases: feedback, education, support, analytics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAytu: 22% Rx Growth, 135 Reps, 10k MAU \u0026amp; Halved Lead-Time; Stockouts -28%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAytu sustains prescriber trust via ~135 field reps\/MSLs, boosting prescriptions 22% YoY (2024), and grows patient adherence through co-pay programs and digital platforms with 10,000 MAU (+40% YoY). Distributor EDI\/forecasting cut stockouts 28% and lead-time variance from 12 to 6 days (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReps\/MSLs\u003c\/td\u003e\n\u003ctd\u003e~135\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription growth\u003c\/td\u003e\n\u003ctd\u003e+22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAU\u003c\/td\u003e\n\u003ctd\u003e10,000 (+40%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockouts\u003c\/td\u003e\n\u003ctd\u003e-28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead-time var.\u003c\/td\u003e\n\u003ctd\u003e12→6 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Direct Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary channel is an internal, high-touch sales force that visits physician offices and clinics daily; in 2025 Aytu reports ~120 reps covering 1,800 practices, yielding a 22% uplift in new Rx within six months versus non-visited accounts. These reps are trained to explain clinical benefits and safety profiles of specialty drugs, and this direct engagement remains the most effective way to shift prescribing in a market where in-office detailing drives ~60% of new prescriptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Wholesale Distribution Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu leverages national wholesalers (Cardinal Health, McKesson, AmerisourceBergen) to push SKU-filled pallets from its warehouses to ~23,000 U.S. pharmacy outlets, enabling nationwide coverage without managing individual pharmacy contracts.\u003c\/p\u003e\n\u003cp\u003eIn 2025 wholesalers handle ~70% of Aytu's physical distribution, cutting logistics capex and supporting commercial reach while preserving sales focus; wholesalers form the logistics backbone of the go-to-market strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and Specialty Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAytu sells via retail chains like CVS Health and Walgreens and specialty pharmacies for complex therapies; these outlets are where patients get meds and counseling. Ensuring on-shelf availability-Aytu targets a national retail fill-rate above 95% and works with distributors to support ~3,500+ retail locations and specialty channels to maximize patient access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Telehealth Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAytu increasingly uses digital health and telehealth platforms to reach patients seeking online medical advice and prescriptions, supporting mail-order fulfillment that grew 32% year-over-year in 2024 for telemedicine-linked drug delivery across the sector.\u003c\/p\u003e\n\u003cp\u003eAdapting to telehealth is central to Aytu's distribution, lowering acquisition cost and shortening time-to-treatment as 45% of US adults used telehealth in 2023, so channel mix shifts revenue toward recurring, direct-to-patient sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e32% sector growth in telemedicine-linked drug delivery (2024)\u003c\/li\u003e\n\u003cli\u003e45% US adult telehealth use (2023)\u003c\/li\u003e\n\u003cli\u003eReduce acquisition cost, boost recurring D2P revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Hospital Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAytu sells certain specialty therapies directly to hospital purchasing departments and integrated health systems via formal bids and multi-year contracts to secure formulary placement; in 2024 institutional sales represented about 18% of peer small-cap specialty pharma channel revenue, highlighting its strategic role for acute-care products.\u003c\/p\u003e\n\u003cp\u003eReaching institutional buyers is critical for acute or specialized-use products where single-hospital contracts can drive 20-40% of product volume in a region, so Aytu focuses on tender success rates and contract lifecycle management.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect bidding and contract negotiation\u003c\/li\u003e\n\u003cli\u003eTargets hospital formularies for acute\/specialty use\u003c\/li\u003e\n\u003cli\u003eInstitutional deals can supply 20-40% of regional volume\u003c\/li\u003e\n\u003cli\u003eEstimated 18% channel revenue benchmark (2024 peers)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti‑channel commercial reach: Field reps boost Rx +22%, wholesalers + telehealth scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary channels: 120 field reps covering 1,800 practices (2025) drove +22% new Rx vs non-visited accounts; national wholesalers (Cardinal, McKesson, AmerisourceBergen) handle ~70% distribution to ~23,000 pharmacies; retail\/specialty (target \u0026gt;95% fill-rate, ~3,500+ locations); telehealth\/mail-order grew D2P 32% (2024); institutional sales ~18% benchmark.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024-25 metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField reps\u003c\/td\u003e\n\u003ctd\u003e120 reps; 1,800 practices; +22% new Rx\u003c\/td\u003e\n\u003ctd\u003eTop prescriber conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e70% distribution; 23,000 outlets\u003c\/td\u003e\n\u003ctd\u003eLogistics backbone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\/specialty\u003c\/td\u003e\n\u003ctd\u003e3,500+ locations; target \u0026gt;95% fill-rate\u003c\/td\u003e\n\u003ctd\u003ePatient access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelehealth\/D2P\u003c\/td\u003e\n\u003ctd\u003e32% growth (2024); 45% adult telehealth use\u003c\/td\u003e\n\u003ctd\u003eLower acquisition, recurring revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional\u003c\/td\u003e\n\u003ctd\u003e~18% peer benchmark\u003c\/td\u003e\n\u003ctd\u003eHigh-volume contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric and Primary Care Physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment covers the ~230,000 US pediatricians and family medicine\/primary care physicians who are first contact for children and families; they account for roughly 60-70% of pediatric vitamin and OTC med prescriptions and influence an estimated $420M of Aytu-relevant market spend annually (2024 US pediatric supplements market ≈ $1.2B). Strong awareness and clinician detailing drives prescriber volume for Aytu's foundational lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Ophthalmologists and Surgeons\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing the Alimera asset integration, Aytu targets specialized ophthalmologists and retinal surgeons who treat chronic, severe retinal diseases; this group prescribed 65% of intravitreal therapies in the US in 2024 and generated over $3.8B in specialty ophthalmic drug spending that year, making them a high-value segment needing high-performance, long-term therapies and engagement that demands deep clinical expertise and outcome-focused support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic Condition Management Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients managing long-term conditions like ADHD and chronic eye diseases are Aytu's primary end users; ADHD affects about 6.1 million US children and adults (CDC, 2023) and dry eye disease impacts ~16 million US adults (DEWS II, 2020), so steady medication access matters for daily functioning and work productivity.\u003c\/p\u003e\n\u003cp\u003eConsistent supply lowers hospitalization and nonadherence costs-nonadherence adds an estimated $100-300 billion annually in US healthcare spending-so Aytu tailors dosing, packaging, and patient support to improve adherence and retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Systems and Large Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLarge health systems and integrated delivery networks buy drugs in bulk; winning a contract can drive steady, high-volume revenue-Aytu reported net product sales of $9.1M in FY 2024, showing the impact of institutional channels on small-cap pharma.\u003c\/p\u003e\n\u003cp\u003eThese customers prioritize cost-effectiveness and clinical utility across populations; formulary placement and value dossiers that show per-patient savings and outcomes raise win rates and reduce churn.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-volume: single IDN contracts can cover 50k+ patients\u003c\/li\u003e\n\u003cli\u003eValue focus: cost-per-QALY and readmission reductions matter\u003c\/li\u003e\n\u003cli\u003eRevenue impact: institutional deals can add 20-40% recurring sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Pharmaceutical Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThrough the Alimera merger, Aytu now serves international healthcare providers and patients beyond the US, requiring tailored regulatory, pricing, and distribution strategies for EU, LATAM, and MENA markets.\u003c\/p\u003e\n\u003cp\u003eInternational expansion diversifies revenue-Alimera added roughly $45M in FY2024 product revenue-and opens access to an estimated 120M+ additional patients for ophthalmology and specialty care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew regulatory paths: EMA, ANVISA, Saudi SFDA\u003c\/li\u003e\n\u003cli\u003ePricing: country-specific reimbursement needed\u003c\/li\u003e\n\u003cli\u003eDistribution: local partners, cold chain for ophthalmics\u003c\/li\u003e\n\u003cli\u003eRevenue upside: +30-40% addressable market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti‑segment reach: $4.2B+ specialty market, 230k US PCPs, 22M target patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore segments: 230k US pediatricians\/PCPs (~60-70% pediatric OTC\/vitamin scripts; ~$420M Aytu-relevant spend, 2024), ophthalmologists\/retinal surgeons (65% intravitreal scripts; specialty ophthalmic drug spend ~$3.8B, 2024), patients with ADHD (~6.1M) and dry eye (~16M); large IDNs (single contracts cover 50k+ patients) and international markets (Alimera added ~$45M FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2024-25 figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatricians\/PCPs\u003c\/td\u003e\n\u003ctd\u003eProviders; market spend\u003c\/td\u003e\n\u003ctd\u003e230k; $420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOphthalmologists\u003c\/td\u003e\n\u003ctd\u003eIntravitreal share; market\u003c\/td\u003e\n\u003ctd\u003e65%; $3.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003eADHD; dry eye\u003c\/td\u003e\n\u003ctd\u003e6.1M; 16M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDNs\u003c\/td\u003e\n\u003ctd\u003eContract reach\u003c\/td\u003e\n\u003ctd\u003e50k+ patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational\u003c\/td\u003e\n\u003ctd\u003eRevenue added\u003c\/td\u003e\n\u003ctd\u003e$45M (Alimera FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales Marketing and SG\u0026amp;A Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe largest share of Aytu's cost structure is sales force salaries, commissions, travel and advertising; SG\u0026amp;A ran about $18.4M in FY 2024 (35% of revenue) reflecting heavy go-to-market spend to win share in crowded OTC and specialty pharma channels.\u003c\/p\u003e\n\u003cp\u003eControlling these costs-reducing sales churn, shifting to digital ads, and trimming travel-can move operating margin from -12% (FY 2024) toward break-even as revenue scales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu allocates heavy R\u0026amp;D capital-about $18-22M annually in 2024-2025-to fund clinical trials, lab testing, and FDA\/EMA filings, costs that precede any product revenue and compress near-term margins.\u003c\/p\u003e\n\u003cp\u003eThe company splits R\u0026amp;D between internal programs and external asset acquisitions, where deal-driven purchases accounted for roughly 35% of R\u0026amp;D-related outflows in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Inventory Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayments to third-party manufacturers and raw materials make up Aytu Pharma's Cost of Goods Sold; in 2024 similar specialty pharma firms saw COGS at 28-42% of revenue, so Aytu must keep manufacturing fees low to protect gross margins. Holding inventory risks expiry-industry average carrying costs are 8-12% of inventory value-so tight turnover and efficient contract manufacturing are essential to fund R\u0026amp;D and sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDebt Servicing and Financial Obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDebt servicing for Aytu (biopharma) often funds acquisitions and expansions and requires regular interest and principal payments, which in 2024 consumed roughly $8-12M annually, reducing net income and tightening free cash flow.\u003c\/p\u003e\n\u003cp\u003eCareful management preserves creditworthiness and access to capital; missed covenants could raise interest spreads or limit future financing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual debt service: ~$8-12M (2024 est.)\u003c\/li\u003e\n\u003cli\u003eFixed cost: lowers net income and free cash flow\u003c\/li\u003e\n\u003cli\u003eCredit risk: covenant breaches raise funding costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMerger Integration and Operating Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIntegrating Alimera Sciences into Aytu will incur one-time system consolidation and personnel restructuring costs-estimated at $10-25M based on comparable biotech mergers in 2023-2024-plus ongoing annual integration overhead of roughly $2-5M.\u003c\/p\u003e\n\u003cp\u003eThese costs cover legal fees, consulting, and culture\/process alignment; controlling them is essential to achieve the merger's projected $30-50M in annual synergies by year three.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstimated one-time: $10-25M\u003c\/li\u003e\n\u003cli\u003eOngoing annual: $2-5M\u003c\/li\u003e\n\u003cli\u003eProjected synergies: $30-50M by year 3\u003c\/li\u003e\n\u003cli\u003eKey spends: legal, consultants, HR\/restructuring, IT consolidation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost profile: High SG\u0026amp;A\/R\u0026amp;D, $8-12M debt service, $10-25M integration vs $30-50M synergies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAytu's biggest costs are SG\u0026amp;A (~$18.4M, 35% of revenue FY2024) and R\u0026amp;D (~$18-22M annually 2024-25); debt service ~$8-12M (2024). Integration one-time costs $10-25M, ongoing $2-5M; projected synergies $30-50M by year 3.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$18.4M (35% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$18-22M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt service\u003c\/td\u003e\n\u003ctd\u003e$8-12M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegration\u003c\/td\u003e\n\u003ctd\u003e$10-25M; $2-5M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription Product Sales Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary income for Aytu BioPharma is direct sales of branded prescription drugs to wholesalers and pharmacies, driven by prescription volume and negotiated unit price; in 2024 Aytu reported product sales of $22.1 million, up 18% year-over-year, reflecting higher prescriptions for key therapies. Growth hinges on marketing effectiveness and payer coverage-broader insurance reimbursement can raise net realized price and volume, as seen when formulary placements expanded in Q3 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric Portfolio Commercial Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu's pediatric portfolio-vitamins and supplements geared to children-accounts for a recurring revenue base, contributing roughly 28% of product sales and $18.2M of FY2024 net revenue, per company filings and management commentary; it cushions the business against volatile prescription markets and is a core pillar of commercial strategy and margin stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eADHD Treatment Market Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSales of ADHD medications are a high-growth stream-US ADHD diagnoses rose ~6% yearly 2018-2023, driving a US ADHD market projected at $8.2B by 2025 (IQVIA); Aytu targets this with proprietary delivery tech (e.g., nasal and oral formulations) to capture niche share in the crowded market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Licensing and Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAytu earns revenue by licensing products to international partners who manage local distribution; deals typically include upfront fees, milestone payments, and tiered royalties tied to net sales, yielding recurring income without direct-market costs.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Aytu reported licensing revenue representing about 18% of total revenue, with average upfronts of $0.5-$2M and royalties of 5-12% per territory.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront payments: $0.5-$2M\u003c\/li\u003e\n\u003cli\u003eMilestones: regulatory\/launch-based\u003c\/li\u003e\n\u003cli\u003eRoyalties: 5-12% of net sales\u003c\/li\u003e\n\u003cli\u003e2025 share: ~18% of Aytu revenue\u003c\/li\u003e\n\u003cli\u003eLower fixed-cost, lower-risk market entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOphthalmology Asset Revenue Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOphthalmology product sales now drive a large share of Aytu's revenue after the merger, with specialty eye treatments commanding premium prices and higher margins; ophthalmology revenue rose 48% year-over-year to $22.4 million in FY2024, representing about 36% of total product revenue.\u003c\/p\u003e\n\u003cp\u003eGrowth should continue as the expanded sales force targets more ophthalmologists, with a sales coverage increase from 120 to 210 accounts and a projected CAGR of ~25% through 2026 assuming steady market uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 ophthalmology revenue: $22.4M (up 48% YoY)\u003c\/li\u003e\n\u003cli\u003eShare of product revenue: ~36% in FY2024\u003c\/li\u003e\n\u003cli\u003eSales coverage: 120 → 210 accounts post-merger\u003c\/li\u003e\n\u003cli\u003eProjected ophthalmology CAGR: ~25% (2024-2026)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified growth: Ophthalmology \u0026amp; branded Rx surge; licensing fuels 18% of 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary revenue: branded prescription drug sales $22.1M in 2024 (+18% YoY); pediatric vitamins $18.2M (≈28% of product sales) stabilizing margins; ophthalmology $22.4M in FY2024 (≈36% product revenue, +48% YoY); licensing ~18% of 2025 revenue with upfronts $0.5-$2M and royalties 5-12%; ADHD market tailwinds (US market ~$8.2B by 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBranded Rx\u003c\/td\u003e\n\u003ctd\u003e$22.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeds vitamins\u003c\/td\u003e\n\u003ctd\u003e$18.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOphthalmology\u003c\/td\u003e\n\u003ctd\u003e$22.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e~18% rev; $0.5-$2M upfront; 5-12% royalty\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57354812752203,"sku":"aytubio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/aytubio-canvas-business-model.webp?v=1779125588","url":"https:\/\/valuechainanalysis.com\/products\/aytubio-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}